Visiongain Publishes Digital Clinical Supply Chain Market Report 2020-2030

26 June 2020
Pharma

Visiongain has launched a new pharma report Digital Clinical Supply Chain Market Report 2020-2030: Forecasts by Component (Software, Services), Type (Inventory Management, Bulk Drug Management, IVRS/IWRS Management, Others), Delivery Mode (On-Premises, Cloud-Based, Web-Based), End-User (CRO’s, Pharma & Biotech, Others), and Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). PLUS COVID-19 Impact Scenarios.

The global digital clinical supply chain market is anticipated to reach US$xyz million in 2030 from its previous value of US$xyz million in 2020. The overall growth rate for the forecast period 2020 to 2030 is predicted to be xyz%.

To access the data contained in this document please email contactus@visiongain.com

Clinical trials are getting more global, complex, focused, and large, with CROs facing added pressure to complete them faster. A few pressing challenges that contribute to increased uncertainty in the value chain include:
• Unpredictable trial duration and staggered subject recruitment.
• Processes related to the management of overage products, monitoring of shelf-life and expiry, regulated transportation, compliance with labeling requirements in global trial scenarios, and re-labeling that suffer due to lack or restricted real-time visibility in clinical material location.
• Trade compliance, if not managed properly, leads to delays in customs clearance, impacting timelines, and the ability to predict Expected Time of Arrival accurately.
• Sub optimized and/or unreliable processes impact the drug reconciliation process, leading to trial closure delays and compliance issues.

"Pharmaceutical companies are widening their footprints to new countries for their clinical trials. They are also expanding their portfolio in developed markets and launching new products in developing markets more rapidly to minimize or contain costs. Clinical trials are also undergoing improvements in guidelines implementation, adaptive clinical trials (or virtual clinical trials), and strict criteria for product labeling. The growing trend of outsourcing and the growth of specialist organizations provide permutations and combinations provided between trial sites, clinical products and services result in an increasing number of nodes in the supply chain."
Industry Analyst, Visiongain 2020

The supply chain for clinical trials is broad, complex and global, involving many stakeholders ranging from raw material manufacturers, distributors, and marketers to clients. Complex industry trends indicate a need for more integrated IT strategies that can tackle emerging challenges around the supply chain of clinical trials. The introduction of Internet-of-Things, RFID allowed clinical supplies, controlled temperature shipping and developments in mobile technology have helped improve data gathering through the clinical trials supply chain.

Currently, strategies such as, acquisitions, mergers, partnerships, collaborations, and launching new products have helped the key players to establish and fortify their position in the global digital clinical supply chain market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the digital clinical supply chain market. For instance, in December 2018; global CRO Parexel partnered with pharma giant Eli Lilly to support building clinical trial learning and development program in China. The effort was part of the two companies' hope to help drive innovation in China’s biopharmaceutical industry by bringing high-value training opportunities to the country’s clinical trial sites and investigators.

Some of the companies operating across the global digital clinical supply chain industry are Almac Group, Fisher Clinical Services, Inc., Parexel International Corporation, Endpoint Clinical, Inc., Sharp, OmniComm Systems, Signant Health, Marken, Oracle, Catalent, Inc., Covance Inc., and PRA Health Sciences among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever